Quest Diagnostics (DGX) Expected to Announce Earnings on Tuesday

Quest Diagnostics (NYSE:DGX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, July 22nd. Analysts expect the company to announce earnings of $2.56 per share and revenue of $2.73 billion for the quarter.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.15 by $0.06. The company had revenue of $2.65 billion during the quarter, compared to analysts' expectations of $2.63 billion. Quest Diagnostics had a net margin of 8.81% and a return on equity of 15.11%. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Stock Down 0.9%

NYSE:DGX traded down $1.46 on Friday, reaching $166.72. The stock had a trading volume of 764,191 shares, compared to its average volume of 1,155,932. The company has a current ratio of 1.44, a quick ratio of 1.31 and a debt-to-equity ratio of 0.84. Quest Diagnostics has a 12-month low of $137.71 and a 12-month high of $182.38. The company has a 50-day moving average of $175.15 and a 200 day moving average of $168.84. The stock has a market cap of $18.61 billion, a P/E ratio of 21.07, a price-to-earnings-growth ratio of 2.33 and a beta of 0.49.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 21st. Stockholders of record on Monday, July 7th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, July 7th. This represents a $3.20 annualized dividend and a dividend yield of 1.92%. Quest Diagnostics's payout ratio is 40.46%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DGX shares. Redburn Atlantic started coverage on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $195.00 price target on the stock. Evercore ISI raised their price objective on shares of Quest Diagnostics from $175.00 to $180.00 and gave the company an "in-line" rating in a research note on Wednesday, April 23rd. Truist Financial raised their price objective on shares of Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday, April 23rd. Wall Street Zen lowered shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Redburn Partners set a $195.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $185.73.

Insider Activity

In other Quest Diagnostics news, SVP Mark E. Delaney sold 874 shares of Quest Diagnostics stock in a transaction on Monday, May 12th. The shares were sold at an average price of $175.72, for a total transaction of $153,579.28. Following the completion of the sale, the senior vice president owned 8,372 shares of the company's stock, valued at $1,471,127.84. This trade represents a 9.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 8.16% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Quest Diagnostics stock. Brighton Jones LLC purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,144 shares of the medical research company's stock, valued at approximately $323,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.